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Prokaryotes have developed numerous innate immune mechanisms in order to fend off 
bacteriophage or plasmid attack. One of these immune systems is clustered regularly 
interspaced short palindromic repeats (CRISPR). CRISPR-associated proteins play a key 
role in survival of prokaryotes against invaders, as these systems cleave DNA of foreign 
genetic elements. Beyond providing immunity, these systems have significant impact 
in altering the bacterial physiology in term of its virulence and pathogenicity, as well as 
evolution. Also, due to their diverse nature of functionality, cas9 endoribonuclease can 
be easily reprogrammed with the help of guide RNAs, showing unprecedented potential 
and significance for gene editing in treating genetic diseases. Here, we also discuss the 
use of NgAgo–gDNA system in genome editing of human cells.
Keywords: CRiSPR–Cas, Cas9, sgRNA, gene expression, gene editing
iNTRODUCTiON
In the late 1800s, scientists reported that, in India, water from two rivers, Ganges and Yamuna, 
have an antibacterial agent that killed Vibrio cholera (1). These antibacterial agents, later termed 
as bacteriophages (from “bacteria” and the Greek word phagein, “to devour”), have important role 
in treatment of various diseases. However, phages still have to attain their therapeutic potential in 
clinical settings; the role and importance of bacteriophages in medical and environmental science 
is currently reaching a new crescendo. Marine virologist reported, in 1980s, that 1 L of sea water 
contains round about 10  billion bacteriophages. Hence, today these viruses (bacteriophages) are 
generally considered as the most abundantly found diverse biological entities on Earth (2, 3).
The ability of prokaryotes to withstand viral attacks is a key for their survival. With the passage 
of time, bacteria have managed themselves according to various inhospitable habitats, such as harsh 
environmental conditions and various bacteriophages attack. Bacteria are able to withstand these 
challenging conditions due to their flexibility in their genetic repertoire and genome homeostasis 
and avert bacteriophage predation with the help of their defense system. One important point 
regarding eubacteria is that they have managed to control their genome size by balancing the uptake 
of material that is beneficial along with tactical loss of redundant genes, in a dynamically designed 
dance with offensive mobile genetic elements (MGEs) like plasmids, viruses, and transposons (4). 
However unlike eukaryotes, prokaryotes have the ability to orchestrate this without expansion of 
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their genome. Recently, it was discovered that clustered regularly 
interspaced short palindromic repeats (CRISPR) and its related 
proteins (cas) play vital role in providing adaptive immunity in 
prokaryotes and archaea against viruses and plasmids, and it has 
been established that this system serves as a guardian of bacterial 
genomes (5, 6).
This system has been found within 90% of archaeal and 45% 
of bacterial genomes that play role as an immunity-like resistance 
in these microorganisms against viruses and plasmids (7). The 
CRISPR–cas system consists of a genetic locus that contains the 
CRISPRs, non-repetitive, unique spacer sequences, and adjacent 
6–20 genes encoding the cas (CRISPR-associated) proteins (8). 
The repeats that are present within each CRISPR locus are highly 
conserved and their base pairs range varies between 23 and 47. 
However, in case of spacers, the range of base pairs varies between 
21 and 72, and these are composed of extrachromosomal elements 
(9). In most cases, the CRISPR loci contains less than 50 repeat/
spacer units, but, in some species, like Chloroflexus spp., contain 
repeat/spacer units up to 375 (9). CRISPR–cas locus can also 
be located in a microbial genome. For example, the genome of 
Methanocaldococcus jannaschii contains 18 CRISPR–cas loci (8).
However, recently conducted studies revealed that CRISPR 
system has other functional roles beyond adaptive immunity. 
Due to novel roles of CRISPR systems in which these systems not 
only expand functional repertoire but also point out the need to 
manage safe-keeping of genome integrity and uptake of MGEs 
that are beneficial for adaptive purposes. Here, in this review, we 
not only discuss CRISPR–cas system role in adaptive immunity of 
prokaryotes along with their role in altering the bacterial physiol-
ogy but also discuss CRISPR systems impact in the evolution of 
bacterial genome, regulation of gene expression, as well as their 
use in various medical and bio-engineering fields.
HiSTORY OF CRiSPR–Cas SYSTeM
Some researchers in 1987 cloned and sequenced the iap gene that 
is present in Escherichia coli and responsible for the conversion 
of alkaline phosphatase isoenzyme (10). Later, a subsequent study 
was conducted on the iap gene by scientists, and they reported 
that set of 29-nucleotide (nt) repeats separated by unrelated, 
non-repetitive, short sequences called as spacers (11). So, this was 
the first report about CRISPR locus and, later, same findings has 
been also observed, when scientists did gene or complete genome 
sequencing in bacteria and archaea (12–15). This availability of 
knowledge about genomic sequences helps in the identification 
of CRISPRs that are present in many such species (16).
For this particular structure of loci, the term CRISPR was used 
first time in 2002 (17). Typically, a repeat cluster has an AT-rich 
region, which is present at leader sequence; in intra-species, this 
sequence is 100 base pair long, but not in interspecies (17). A set 
of protein coding genes also known as CRISPR-associated (cas) 
genes are normally present on one side of loci. Spacer sequence 
analysis in various CRISPR loci showed that these spacers have 
identical sequences to invader’s genetic elements such as plasmids 
and bacteriophages (18, 19). In the early studies, it was revealed 
that there is a relationship among phage sensitivity and the 
absence of spacers, matching the sequence against that specific 
phage, indicating the role of CRISPR loci in immune function 
(18). The CRISPR loci on comparison from various Yersinia 
pestis strains indicates that spacer acquisition occur in a polarized 
fashion in term of new units and are added at leader end of cluster 
(19). In the light of these studies, it was revealed that there is 
an existence of mechanism which not only exploits the potential 
of nucleic acid base-pairing but also enables the sequence-based 
interfering of gene expression, phage infection, or both. With the 
help of detailed bioinformatics analysis of cas genes, this pos-
sibility was supported, and it showed a bias toward proteins that 
are anticipated to facilitate nucleic acids transactions, led to the 
suggestion that CRISPR immunity might work in a similar way 
as the eukaryotic RNAi, that also uses nucleic acid sequences in 
order to control gene-silencing pathway (4, 8).
In 2007, a study was conducted on phage infection in 
Streptococcus thermophiles, which revealed that CRISPR loci 
have key role in adaptive immunity (20). This study gives the first 
experimental proof that sequence similarity among spacer and 
protospacer is a key for CRISPR immunity. More recently, it was 
revealed that CRISPR-based interference can also limit plasmid 
conjugation in Staphylococcus epidermidis, which indicates wide 
spectrum role of CRISPR system in the prevention of horizontal 
gene transfer (HGT) in bacteria (21).
FATe OF CRiSPR SYSTeM AGAiNST 
iNvADiNG DNA
The mechanism of CRISPR–cas system can be categorized into 
three stages as shown in Figure 1. First step: which is also called 
as adaptation (22, 23), immunization (9), or acquisition of spacer 
(24, 25), involves the spacer integration between two contiguous 
repeat units that are present within the CRISPR locus after the 
recognition. Primarily, the spacers are incorporated at leader 
end of CRISPR locus; therefore, position of spacer in locus gives 
the information about its acquisition event. Incorporation of 
viral genome sequence (Spacer) into CRISPR locus termed as 
protospacer (26). In most cases, a very short section of conserved 
nucleotides present near the protospacer vicinity, called as 
CRISPR motif or protospacer adjacent motif (PAM), it appears 
that this motif is very essential in the process of DNA fragment 
acquisition (27, 28). Cas1 and cas2 are the key proteins required 
in first phase because these proteins have significant role in spacer 
acquisition in those genomes which have CRISPR–cas system.
Clustered regularly interspaced short palindromic repeats 
expression is the second stage of this system immune mechanism. 
In this stage, transcription of pre-CRISPR RNA (pre-crRNA) 
occurs with the help of RNA polymerase (RNAP) from the 
CRISPR locus. After the transcription, pre-crRNA cleaves with 
the help of specific endoribonucleases into small CRISPR RNAs 
(crRNAs). On the basis of their function, these crRNAs are termed 
as guide RNAs (29, 30) or prokaryotic silencing RNA (psiRNAs) 
(4, 31). In the final stage, which is also referred as interference 
(27) or immunity (22), multi-protein complex having mature 
crRNAs can recognize and form base pair, which is specific to 
incoming invader’s DNA or RNA having perfect or almost perfect 
complementarity (29). This helps in initiating the cleavage of 
FiGURe 1 | Mechanism of CRiSPR–cas immunity divided into three stages. Stage 1: spacer acquisition. In the first stage, specific fragments of virus or 
plasmid double stranded are integrated at the leader end of CRISPR array on host DNA. A CRISPR array consists of unique spacer (red box) interspaced between 
repeats (blue box). Spacer acquisition occurs in the presence of cas1 and cas2 proteins, which are present near the vicinity of CRISPR array. Stage 2: biogenesis of 
crRNA. In this stage, RNA polymerase at leader end helps in the transcription of Pre-CRISPR RNA (Pre-crRNA) to mature crRNA. Stage 3: interference. In the final 
stage, specific match between crRNA spacer and target sequence leads to the cleavage of foreign genetic elements (blue and red strips).
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crRNA–invader nucleic acid complex (22). However, if there are 
any mismatches between target DNA and spacer or there is any 
mutation in the PAM, then the process of cleavage is not initi-
ated. In this circumstance, viral replication proceeds as targeting 
of DNA is not possible, leading to susceptibility of host to the 
virus attack, resulting in lysis of host. As a result of this, viruses 
released from lysed host cells can kill other susceptible host cells. 
In order to properly operate as a defense system, functionality of 
all three stages is a key; however, it is also important to note that 
each stage is not dependent on the other stage, both temporally 
and mechanistically.
CLASSiFiCATiON OF CRiSPR-Cas SYSTeM
Cas1 and cas2 proteins are genetically present throughout all types 
and subtypes, but there are also some proteins that are present 
specifically in each system. Like, cas3 protein present in type I, 
cas9 protein present in type II, and cas10 protein present only in 
type III system. Up till now, phylogenetically, only type II systems 
have been identified in bacteria, but there is a bias about type I 
systems and type III systems in bacteria, hyperthermophiles, and 
archaea, respectively.
TYPe i CRiSPR SYSTeM
Most widely distributed system in archaea and bacteria is 
CRISPR–cas system type I (32). This system consists of six 
subtypes (A–F), all of these subtypes have cas3 gene. This gene 
has two domain: N-terminal HD phosphohydrolase domain 
and second one is a C-terminal DExH helicase domain (4, 32). 
However, in some subtypes like A, B, and D, there are other genes 
that encode both nuclease and helicase domain. In all subtypes of 
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this system, these two domain work together by cleaving the HD 
domain and unwinding of helicase domain in order to degrade 
DNA. However, as cas3 alone unable to recognize the invading 
DNA, so it also cannot defend cells against infection (29, 33). In 
each subtypes of this system, there are specific subtype cas proteins 
that assemble into crRNA-guided surveillance complexes. These 
complexes help in finding and binding of the target sequences 
which are complementary to the crRNA spacer.
The first crRNA-guided surveillance complex for antiviral 
defense was described in E. coli K12 (type I-E) (29, 33). This 
complex is made up of five functionally important Cas proteins 
(33). Cas6e is an endoribonuclease (previously known as CasE or 
Cse3) that helps in cleaving the long CRISPR RNA into mature 
61-nt crRNAs (29, 34). This mature crRNA remains attached 
with the CASCADE complex, helps in detection of DNA match, 
and cleaves the foreign DNA when found (35) (Figure 2A). This 
crRNA and Cas6e are necessary for the stability and assembly 
of Cse1, Cse2, Cas7, and Cas5. Some researchers recently 
determined Cascade complex structure with the help of cryo-
electron microscopy (cryo-EM) (36). So, the detailed study of this 
structure helps us in understanding how this crRNA is protected 
by the cas proteins and also makes possible for crRNA to form 
base pair which is complementary to the foreign nucleic acid. As 
crRNA forms a complementary base pair with target DNA strand, 
relocating non-complementary strand results in the formation of 
R loop like structure (33).
This crRNA-guided surveillance complexes have been found 
in various subtypes of type I system, such as in S. solfataricus (type 
I-A) (38), Bacillus halodurans (type I-C) (39), and Pseudomonas 
aeruginosa (type I-F) (36).
TYPe ii CRiSPR SYSTeM
This system has four genes: cas1, cas2, cas9, and csn2 in case 
of type IIA or cas4 in case of type II-B. However, the cas9 is a 
signature gene of this system that encodes a multifunctional 
protein that not only play role in the biogenesis of crRNA but also 
cleaves foreign DNA (40, 41). The biogenesis of crRNA in type II 
system is different as compared with other two systems, because 
trans-activating crRNA (tracrRNA) is necessary for this system. 
In Streptococcus pyogenes, tracrRNA is encoded upstreamly and 
found on reverse strand of the CRISPR–cas locus (40). Fusion of 
tracrRNA and crRNA leads to the formation of dsRNA that is 
responsible for cleaving the RNase III enzyme in cell. Although 
biogenesis of crRNA stops upon cas9 deletion, its specific role in 
this process is not clear (40). However, it was recently revealed that 
for the denaturation of target DNA, cas9 require mature crRNA 
and the tracrRNA (41). Cas9 proteins consists of HNH and RuvC 
domain, former domain helps in cleaving the DNA strand which 
is complementary to the guide crRNA; however, latter domain 
helps in cleaving the strand that is non-complementary (41) as 
shown in Figure 2B.
TYPe iii CRiSPR SYSTeM
Type III system have two subtypes; type III-A and type III-B 
(32). These systems are most commonly found in archaea. 
Both subtypes of this system have cas10 and cas6 genes. Cas6 
also known as endoribonuclease, which is CRISPR-specific, and 
cas10 play role in target interference. Although two subtypes have 
these similarities, still it appears that these two systems target 
chemically different substrates, like S. epidermidis have type 
III-A system and target of this system is DNA (21) and Pyrococcus 
furiosus and S. solfataricus have type III-B systems that target 
RNA (31, 42, 43) (Figure 2C). This basic variation about target 
indicate us functional diversity, which is present within the same 
CRISPR–cas type.
ROLe OF CRiSPR BeYOND ADAPTive 
iMMUNiTY OF PROKARYOTeS
Latest studies about CRISPR system, opens a new gateway, which 
gives us the information that this system has role beyond adaptive 
immunity of prokaryotes (44). There is explosion of reports about 
CRISPR–cas system that helps in the analysis of cost and benefits 
of this system and also expands our knowledge in understanding 
the various roles they play in bacteria. A new perception about 
functions of CRISPR system has evolved, as it has the ability to not 
only control endogenously transcription but also regulates bacte-
rial pathogenicity. A recent study gives us information that this 
system has the ability to regulate endogenous genes, responsible 
for pathogenesis and virulence of Francisella novicida (45, 46). 
It was also shown that type II CRISPR system can repress bacte-
rial lipoprotein transcription that leads to the pro-inflammatory 
response in human host. Incongruously, this immune system 
in bacteria play role in the regulation of those genes, which are 
responsible for encoding of factors that have impact in pathogen-
esis of bacteria. CRISPR immune system also helps bacterium 
to bypass the human immune system. Similarly, very recently, it 
was revealed that CRISPR can change the pathogenic behavior of 
Campylobacter jejuni (47). In Neisseria meningitidis pathogenesis 
and Legionella pneumophila infection also same outcomes has 
been observed by this system (48, 49) (Table 1).
THe evOLUTiON OF CRiSPR SYSTeM 
PLAYiNG AS A DeFeNSe
Several studies on role of CRISPR system working as defense 
system in bacteria and archaea gives us a clue that how this 
system in general interplay coevolutionary between prokaryotes 
and their bacteriophages, and specifically speaking provide 
information about their genetic arms race (50–53). Also, dif-
ferent studies showed that, upon the exposure of viruses, these 
CRISPR loci diversify rapidly in response to that particular 
exposure or virus attack (54, 55). In turn, bacteriophages also 
mutate in order to bypass the CRISPR-based immunity (26, 51). 
In the light of recent study, which has shown a twisted turn of 
event that phage not only acquire but also use this CRISPR sys-
tem of bacterium in their host in order to target antiviral defense 
system, illuminating the evolutionary worth of this system (56). 
Hence, these studies indicate that high frequency rate of muta-
tion were observed in viral genomes, host-virus population 
ecology, with indications that CRISPR immune systems are a 
FiGURe 2 | Mechanism of CRiSPR immunity in all three types of CRiSPR–cas system. In type I system (A), after the spacer acquisition in the presence of 
Cas1 and cas2 protein, biogenesis or processing of Pre-crRNA within the Cascade complex is achieved by cas6 endoribonuclease. Cleavage occurs at the base of 
stem-loop formed by repeat RNA to release mat-crRNA. After that cascade having mat-crRNA recruits the cas3 nuclease in order to nick the DNA strand 
complement to the protospacer, immediately downstream of the interaction region with crRNA spacer. This leads to the breakdown of foreign DNA (black strips). In 
type II system (B), after spacer acquisition, this system utilizes tracrRNA for the biogenesis of crRNA. Pairing between tracrRNA and Pre-crRNA results in the 
formation of double strand substrate, which is cleaved by the host encoded RNase III in the presence of cas9 to liberate the small crRNA (int-crRNA). After the 
liberation of int-crRNA, there is immediate trimming of int-crRNA at 5′ end that yield to mat-crRNA. For target cleavage, crRNA, tracrRNA, and cas9 domains (Ruvc 
and HNH) are necessary. HNH domain helps in cleaving the DNA strand that is complementary to crRNA guide, while Ruvc domain responsible for cleaving the 
non-complementary strand. In type III system (C), processing of Pre-crRNA to int-crRNA occur in the presence of cas6. After that int-crRNAs are incorporated into 
Csm/cas10 or Cmr/cas10 complex, where further maturation occur by trimming at 3′ end sequences that results in the liberation of mat-crRNA. Genetic evidence 
revealed that DNA cleavage occur by sub-type III-A (37), while on the basis of biochemical data, it was revealed that subtype III-B helps in cleaving the RNA 
molecules (31).
TABLe 1 | Bacterial species and their pathogenesis with experimental 
model.
Bacterial species infection experimental model Reference
Campylobacter jejuni Guillain Barre 
syndrome
Human intestinal epithelial 
and HT-29 cells
(47)
Legionella 
pneumophila
Legionnaires’ 
disease
Macrophages and 
aquatic amoebae
(49)
Neisseria meningitidis Meningococcal 
disease
ND (48)
Francisella novicida Tularemia Mice (46)
ND, not described.
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key force for the sustainability of bacterial and evolution of viral 
genome as well.
Clustered regularly interspaced short palindromic repeats 
system protects chromosome against invasive genetic element in 
order to maintain genetic homeostasis, which, in turn, is beneficial 
for the cell, because this system act as a barrier against acquisition 
of foreign element (57, 58). No doubt these invasive elements, such 
as plasmids, phage, and other conjugative elements, sometimes 
carry beneficial genes, which not only play positive role in bacte-
rial adaptation but also have an evolutionary benefit that helps in 
increasing its fitness in the environment, like antibiotic resistance 
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and virulence factors. A recent study reported that targeting of 
CRISPR sequence in bacterial chromosome results in the loss of 
pathogenicity islands (59). This spread is persistent not only in 
case of plasmid encoded-antibiotic resistance cassettes but also 
found in case of HGT of pathogenicity islands among different 
bacterial genomes. There are many examples that indicates estab-
lishment of negative correlation between the occurrence as well as 
diversity of CRISPR system, and existence of phages and plasmids, 
as illustrated in Campylobacter, Enterococcus and many group A 
Streptococcus species (60). However, occurrence of CRISPR loci 
in Enterococcus faecalis and Enterococcus faecium genome is rare, 
and typically 25% of their genome constitute of MGEs (60, 61). 
This can be correlated with the ability of CRISPR–cas systems in 
which this system interfere directly with natural transformation, 
as shown in Staphylococcus (21, 37). More precisely speaking, 
targeting of conjugative plasmids by CRISPR system leads to the 
adverse effect on antibiotic resistance in S. epidermidis (37, 57). 
On the other hand, the paucity of CRISPR loci in Staphylococcus 
aureus likely correlates with plasmids occurrence and other 
MGEs that seems to increase the virulence in this pathogen (57, 
60). Almost same findings have been observed in pneumococci, as 
experiments revealed that CRISPR system can avert the switching 
of capsule for successful infection by Streptococcus pneumoniae 
(59). In terms of cost, when CRISPR system plays as a defense 
in the bacterium, it can result in the loss of key phenotype, such 
as virulence in human pathogens. This trade-off might be a 
possible reason as to why this system existed “only” in half of 
the bacterial population. Moreover, the existence and activity of 
CRISPR immune system indicates not only frequency but also 
richness of ecosystem with predators and invaders, the intensity 
of CRISPR-mediated arms race between virus and host, as well as 
the existence of other defense systems in host, such as restriction–
modification, surface receptor mutation, and abortive infection.
CRiSPR SYSTeM AND iTS ReGULATiON
The key function of CRISPR system is to provide immunity in 
prokaryotes, and the expression of this system’s defense mecha-
nism might be due to invasion of extra chromosomal elements. 
In a recent study, it was proven by the approach of shotgun pro-
teomic study in S. thermophiles that, after phage infection, there 
is an increase in the expression of cas protein (62). Similarly, in 
Thermus thermophiles, there is an increase in CRISPR expres-
sion after phage infection (63). Moreover, in response to UV, 
CRISPR system can be modified which play role in DNA damage 
sensitivity, pointing out its other possible roles in addition to 
neutralization of foreign genetic elements (64, 65). However, up 
to date, very little information is available about CRISPR system 
regulation in response to foreign stimuli and also the periods 
during which this system is not required (64, 65). In case of avail-
ability of beneficial elements, it is favorable to downregulate the 
CRISPR system. However, upon phage exposure, most evidence 
supports CRISPR–cas upregulation. As we all know, effectiveness 
of CRISPR system is not 100%, because some beneficial elements 
will need to be acquiring in order to maintain their selective 
advantage.
Most information about regulation of CRISPR system is 
available for Salmonella enterica serovar Typhi and E. coli hav-
ing type I-E systems. It is established universally that Histone 
like nucleotide structuring protein (H-NS) is a regulator, which 
plays role in bacterial chromosome compacting with the help of 
an AT-rich, curved DNA (66). Several promoters are located in 
the close vicinity of curved DNA. Binding of these promoters 
with H-NS leads to the inhibition of RNAP binding, resulting in 
gene-silencing (66). In E. coli, binding sites of H-NS is present 
near cas operon promotor, so cas gene expression are negatively 
regulated by H-NS (67, 68). It is hypothesized that, when foreign 
genetic elements invade their nucleic acid in the cell, binding 
between H-NS and invading nucleic acid will occur at that time, 
which is due to higher AT-content (69, 70). It is predicted that 
Sequestration of H-NS results in the release of cas and/or LeuO 
promoter which are recognized by RNAP and that leads to activa-
tion of expression, allowing active CRISPR–cas-mediated defense 
(67, 68, 71).
In S. typhi, negative regulator for cas expression is lysine-
responsive regulatory protein (LRP) (72). This protein also works 
like H-NS as LRP binds with cas promoter that results in the 
inhibition of RNAP binding with cas promoter. However, LRP 
has the ability to bind along with H-NS, indicating that these 
two proteins can interact together which results in generation 
of nucleosome structure that leads to the of cas gene (72). It 
is important to note that LRP has no role in regulating the cas 
operon in E. coli, indicating that type I-E CRISPR–cas systems 
work differently at regulatory level in these two closely related 
organisms (67, 72).
LeuO, a LysR-type transcriptional regulator, also competes with 
H-NS in E. coli and S. Typhi, in response to amino acid starvation 
that also results in the repression of cas gene (68, 72, 73). LeuO 
usually binds at flanking region of the cas promoter and as well as 
H-NS binding site. LeuO competes with H-NS for binding with 
DNA, enabling promoter to recognize by RNAP, which facilitates 
cas gene expression (68, 72, 73). During the state of amino acid 
starvation, LeuO expression is increased due to aggregation of 
small molecules of guanosine 3′-diphosphate 5′-triphosphate and 
guanosine 3′,5′-bis (diphosphate) also known as (p) ppGpp (74). 
However, it is interesting to note that when E. coli get infected 
with phage lambda, then there is no accumulation of (p) ppGpp 
(75). In theory, there is a possibility that amino acid starvation 
can be triggered by other phages infection, which results in the 
LeuO-dependent CRISPR–cas system activation.
During the envelop stress, two-component regulatory system 
(BaeR-S) becomes activated (76). Phage infection causes viral 
protein accumulation in membrane that leads to the envelop 
stress. In response to membrane stress, activation of histidine 
sensor kinase BaeS is triggered by phosphorylation, which leads 
to the activation of BaeR protein. After the activation of BaeR, 
this protein enable DNA binding, modulating gene expression 
(76). In E. coli, binding site of BaeR is located near the casA pro-
moter of H-NS binding site. Therefore, binding of BaeR act as an 
antagonist for H-NS binding that leads to release of cas promoters 
for the recognition of RNAP and cas expression (77, 78) as shown 
in Figure 3.
FiGURe 3 | Regulation of CRiSPR–cas system. This network model 
indicates the summary of CRISPR–cas system regulation. Green (E. coli) and 
red (Salmonella) lines with round head indicate negative effects on CRISPR–
cas system regulation. While, triangular arrow head indicates positive effect.
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In summary, regulation of CRISPR–cas systems occurs at 
transcriptional level of cas genes and CRISPR arrays at post-
transcriptional level on cas proteins. Hence, picture of these 
systems, how they are regulated is diverse and far from complete.
GeNe ReGULATiON BY CRiSPR AND iTS 
ROLe iN PATHOGeNeSiS
Francisella novicida is an intracellular bacterial pathogen that 
causes a relatively rare human disease by bypassing the innate 
immune system of host (79). F. novicida has various mechanisms, 
and, with help of these mechanisms, this bacterium subverts the 
host macrophages as well as other immune cells functions. After 
the engulfment of F. novicida by macrophage, this bacterium 
enters phagosome, a compartment having several antimicrobials 
and innate immune recognition receptors (79). Toll-like Receptor 
2 (TLR2) is an example of innate immune receptor, which detects 
BLPs (80, 81). Activation of TLR2 leads to a pro-inflammatory 
response that recruits and activates immune cells, which results 
in combating and clearing of the bacterial pathogen.
The expression of BLP is repressed in F. novicida, because 
this pathogen uses cas9, tracrRNA, and scaRNA as regulator 
which ultimately leads to lowering of BLP level by roughly 2-fold 
in its envelop (45, 82). As a result of this, activation of TLR2 is 
dampened, and it facilitates survivability of pathogen within the 
host. If regulation is not mediated by CRISPR system, F. novi-
cida elicits an inflammatory response that is TLR2-dependent, 
because deletion mutants of cas9, tracrRNA, and sacRNA induce 
more inflammatory response as compared with wild-type bac-
teria (45). This inflammatory response is dependent on both 
TLR2 and overexpression of BLP, as strains lacking the regulatory 
components so BLP initiates a response that is limited only to 
wild-type levels (45, 82). Moreover, deletion mutants are highly 
attenuated (over 1000 fold) as they lack the CRISPR–cas system 
(45). Additionally, cas9, tracrRNA, and scaRNA deletion mutants 
are not able to cause lethal infection in mice, which again empha-
sizes their importance as virulence regulators in F. novicida (45).
Currently, in F. novicida, cas9 is the only known example of 
CRISPR–cas system that acts naturally in a regulatory capacity; 
there are also other observations about other species that use cas9 
as a virulence factor. In a human lung epithelial cell model, in 
order to attach the Neisseria meningitidis to cell surface of the 
host, cas9 is the key for not only invasion but also for intracellular 
replication (45). Also, in a colorectal epithelial cell model, cas9 
is the key for the attachment as well as invasion of C. jejuni (47). 
The exact mechanisms by which cas9 involved as a virulence fac-
tor in these organisms is yet to be known. However, on the basis 
of cas9-established role as a regulator of gene expression in F. 
novicida, it seems that cas9 work in combination with tracrRNA 
or an unidentified small RNA, and regulate specific transcription, 
which eventually play role in the control of virulence properties.
Moreover, cas9 role is correlated with the virulence of 
Campylobacter-specific strains, which encodes the Cst-II sialyl 
transferase, and this Cst-II produces a sialylated lipooligosaccha-
ride. However, cas9 deletion in C. jejuni isolates from GBS patients 
results in the loss of ability to translocate across epithelial cells of 
intestine. Also, cas9 deleted mutants having sialylated LOS that 
bind to human serum more strongly as compared non-mutants, 
which indicate its importance in virulence (47). Interestingly, it 
is hypothesize that in C. jejuni, regulation of CRISPR system may 
not only help to attach efficiently with host cells but also mask the 
surface in order to avoid detection by host receptors that results 
in prevention of immune system activation, like the complement 
system. Since it is known that, in Francisella, membrane BLP 
is a regulatory target of cas9, and these additional examples of 
cas9 contribution to virulence traits which play role in attach-
ment of bacteria to the cell surface of host, so it is speculated 
that CRISPR–cas systems might involve in the composition of 
envelop.
CRiSPR–Cas SYSTeM FACiLiTATeS 
evOLUTiON OF THe GeNOMe
In addition to the regulation of gene expression, CRISPR sys-
tem can play role in the evolution of genome by self-targeting. 
However, as CRISPR–cas systems mostly cleave DNA, the 
chromosomal sequences targeting results in cytotoxicity (59, 
83, 84). CRISPR locus can also be targeted during self-targeting 
of the chromosome (which, by definition, is complementary to 
the CRISPR transcript), or it can also be targeted when foreign 
genomic sequences are incorporated in the form of spacer into 
CRISPR locus, and both these conditions results in the cleavage 
of genome. Self-targeting that leads to cytotoxicity results in the 
selection of avoidance mechanisms, which helps in differentia-
tion of self (CRISPR spacer) and non-self (protospacer) (85, 86). 
Spacers that are derived from chromosome still pose a serious 
threat to the survivability of cell (59), but bioinformatics and 
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experimental analyses has revealed that self-derived acquisition 
of spacer events occur repeatedly (84, 87–89). Generally self-
targeting events are lethal, but, in some cases, cells can survive 
as they acquire mutations that led to the inactivation of self-
targeting. These mutations can also be found in cas genes, spacers, 
repeats, and protospacer targets, and there may be involvement 
of large-scale genome rearrangements, presumably owing to 
repairing of re-combinational DNA, following genomic cleavage 
by CRISPR–cas system (59). For example, in Pectobacterium 
atrosepticum, crRNAs target horizontally acquired chromosomal 
island that is considered as lethal. But, surviving mutants have 
several chromosomal deletions, as well as complete removal 
of targeted ~100 kb island that play role in plant pathogenicity 
(59). Similarly, other chromosomal deletions were also detected 
when CRISPR–cas target other core genes such as lacZ (59). Self-
targeting could actually be beneficial in those rare cases in which 
rearrangement of the genome confers a fitness benefit.
CRiSPR-BASeD APPLiCATiONS
Due to the genetic polymorphism nature of cas genes, along with 
encoding of functionally diverse proteins has set the platform for 
a wide array of applications.
The CRISPR loci can be used for genotyping of prokaryotes, 
such as by the exploitation of CRISPR repeat occurrence and 
their diversity that helps in identification or typing of Yersinia 
and Mycobacterium isolates (19), as defined by spacer oligo 
typing (spoligotyping) (90). Subsequently, spacer content was 
used for genotypic of which provides insight into the strains 
common origin as defined by up keeping of ancestral spacers 
(91). Additionally, polarized spacer at leader end of CRISPR 
locus act as a genetic tape record for immunization events 
and it provides basis for tracking the genetic trajectory of a 
strain. Among others, several bacteria were genotyped with 
the help of these CRISPR loci, such as Corynebacterium, 
Yersinia, Mycobacterium, Pseudomonas, Streptococci, Legionella, 
Salmonella, Escherichia, and Lactobacillus (92, 93). By using this 
approach, it is easy to determine the relatedness of pathogeni-
cally important strains, such as Salmonella and E. coli in case of 
food outbreaks (93).
GeNOMe eNGiNeeRiNG
In the early models of CRISPR systems, it was hypothesized that 
interference was RNA-mediated and protein-dependent, akin to 
the eukaryotic RNA interference mechanism (4). However, it was 
later established that CRISPR–cas primary target is DNA (21), 
and the interference which cleaves DNA is sequence-specific 
(21, 22). These findings opened a new gateway for this system 
subsequent use as programmable nucleases, with many integral 
biotechnological applications.
Due to the detailed study of CRISPR immunity, particularly 
type II, cas9-mediated immunity, led to the realization of poten-
tial use of this enzyme in genetic engineering (40, 41, 58, 94). In 
the year 2013, there was explosion of reports revealing the use 
of cas9 in genome editing, modulation of gene expression, and 
genetic screening (95), which we discuss briefly below.
USe OF CRiSPR–Cas9 AS A TOOL OF 
GeNOMe eDiTiNG iN DiSeASe
The CRISPR–cas9 system is an excellent and versatile tool for 
genomic studies in cells, as this system can be used in dis-
secting the gene function in various biological processes and 
diseases as well (96–98). CRISPR–cas9 system makes genome 
editing as a simple technique, which is before a major technical 
challenge. Before the use of CRISPR–cas9 system as a genome-
editing tool, Zinc finger nucleases (ZFNs) and Transcriptional 
activator-like effector nucleases (TALENs) were used for 
genome editing. These two systems use proteins for the recog-
nition of specific sequences in the genomic regions; however, 
CRISPR–cas system use only sgRNA for editing. The simple 
and easy use of sgRNA has led to worldwide acceptance for 
genome editing. The CRISPR–cas system now use as an alter-
native of ZFNs and TALENs due to its adaptability, simpler 
in assembly, as well as higher specificity and efficiency (99). 
Unlike ZFNs and TALENs, CRISPR–cas9 target specificity is 
determined by the DNA complementary sequence of sgRNA, 
which helps in easy construction of knockout reagents. For 
example, this system has been used in creation of knockout 
of the CCR5 and C4BPB genes in human myeloid leukemia 
K562 cells (100).
Over the past decade, there are explosion of reports about the 
studies of human cancer at molecular level; however, there is still 
need to understand that which mutations play their part in the 
initiation and progression of tumor. Noteworthy, CRISPR–cas9 
system can target complex genetic diseases such as cancer, 
because this technology has ability to target multiple mutations 
at the same time. Such as cas9 can be used with combination 
of sgRNA in order to target more than one genomic loci (101, 
102). Recently, some scientists developed CRISPR–cas9-based 
approach in which they investigate the genes responsible for 
cancer in mouse model (103).
The CRISPR–cas9 system has been also used for the generation 
of tumor-associated chromosomal translocations, this occurs 
during the carcinogenesis via illegitimate non-homologous join-
ing of two chromosomes. As CRISPR–cas9 has the ability to cause 
double strand breaks at precisely defined positions that enables 
cancer cell lines and primary cells generation with chromosomal 
translocations and these cells found to replicate in cancers such 
as Ewing’s sarcoma, AML (104), and lung cancer (105). Recently, 
another group of scientists developed an efficient in vivo method 
that results in the specific chromosomal rearrangements, when 
they introduce CRISPR–cas9 system to somatic cells of adult 
mice (106). In NSCLC (Human non-small cell lung cancers), an 
oncogene namely EML4-ALK is present, and CRISPR–cas9 sys-
tem was used to create a mouse model of Eml4-Alk-driven lung 
cancer. The resulting tumors were inverse of Eml4-Alk, express 
the Eml4-Alk fusion gene that display histopathological as well 
as molecular features akin to human NSLCs, and respond with 
treatment of ALK inhibitors.
This technology has an unresolved issue called as off-target 
effects. In order to overcome off-target effects, researchers has 
developed new technology in which they use the mutated 
active site of RuvC which converts cas9 into a nickase, by using 
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two-paired guides, which direct nicking at two adjacent sites only 
in a desired target sequence (107–109). In spite of this caveat, 
cas9-directed genome editing has been successfully used in a 
wide range of hosts and cell lines that include human cells, plants, 
rats, mice, zebrafish, nematodes, yeast, bacteria, and also many 
other organisms (95), creating a revolution in molecular biology.
USe OF CRiSPR–Cas9 iN CURiNG HUMAN 
GeNeTiC DiSeASeS
Gene therapy can be used for curing human genetic disease by 
correcting the mutations, which play role in causing disease. 
Recently, there is a ground-break study about CRISPR–cas9 
technology, in which scientists repaired cystic fibrosis trans-
membrane conductance regulator (CFTR) locus in those patients 
having cystic fibrosis by homologous recombination in cultured 
intestinal stem cells. CFTR is a genetic disorder that primarily 
affects lung and digestive system (110). After correction of CFTR 
locus by CRISPR–cas9, it was found out that corrected gene not 
only expressed but also fully functional, as CFTR locus retain its 
ability of cAMP-induced intestinal stem cell organoid swelling, 
that is lost in CFTR-mutated cystic fibrosis patients. Hence, this 
study reveals that there is possibility of curing patients who have 
monogenic hereditary defect by correction of gene in stem cells. 
In another study, in which scientists adopt in vitro method, they 
successfully transplanted organoids into the colons of mice (111). 
These two studies reveal the potential on future of gene therapy in 
those patients having cystic fibrosis (110).
In human beings, one of the most common genetic diseases is 
β-thalassemia that is caused by mutation in human hemoglobin 
beta (HBB) gene. Recently, a study reveals that CRISPR–cas9 cleave 
HBB gene with combination of piggy-Bac transposon (MGEs that 
efficiently transposes between vectors and chromosomes), which 
helps in correcting the mutation of two different β-thalassemia, 
resulting in conversion of homozygous β-thalassemia to het-
erozygous in induced pluripotent stem cells (iPSCs) from those 
patients having this disease (112). During the correction of 
iPSCs, no off-target effects were detected and cells retain its full 
pluripotency and also exhibit their normal karyotypes. In culture, 
when differentiated into erythroblasts, it was revealed that these 
gene-corrected iPSCs retained HBB expression as compared with 
the parental iPSCs line. Hence, this study offers another strategy 
in curing disease as corrected iPSCs display its normal functions 
and also can be used as a source of cells for transplantation in 
those patients having this disease (112).
In the light of several recent studies, it was revealed that for 
the correction of genetic diseases, CRISPR–cas9 can also be used 
in small mammal models. In rodents, desired mutation can be 
generated in single step by using the zygote injection of cas9 
mRNA and sgRNA. For example, a study revealed that mice 
having mutated Crygc gene responsible for cataracts could be 
rescued by zygote injection of cas9, mRNA, and sgRNA (97).
Recently, a study revealed no off-target effects during gene 
editing in cynomolgus monkeys upon co-injection of cas9, 
mRNA, and sgRNA into one cell stage embryo (113). Hence, 
this achievement has considerably significant impact because 
monkeys are considered as model species for studying human 
diseases, and this strategy can help in developing new therapeutic 
approaches.
Moreover, some scientists, in 2016, reported that they develop 
new approach for gene editing (base editing), which irrevers-
ibly converts the one DNA base into another one without the 
requirement of a donor template or the cleavage of dsDNA. 
They engineered CRISPR–cas9 fusion with cytidine deaminase 
enzyme that has the ability to be programmed with a guide RNA, 
without the cleavage of dsDNA, and facilitates directly conver-
sion of cytidine to uridine, thus effecting the substitution of 
C to T or (G to A). As a result of base editing, cytidine con-
verts approximately within a window of five nucleotides, and 
corrects efficiently various point mutations relating to human 
disease (114).
Similar to cas9 gene-editing technique, a group of scientists 
took endonucleases from the Argonaute protein family which 
uses oligonucleotides for the degradation of invader’s genome. 
They reported that the Natronobacterium gregoryi Argonaute 
(NgAgo) is DNA-guided endonuclease, which play role in genome 
editing in human cells. NgAgo interact with ~24 nucleotides of 
5′ phosphorylated single stranded guide DNA (gDNA), creating 
site specific dsDNA breaks. As in the case of cas9, PAM is not 
required by NgAgo–gDNA system. Upon preliminary characteri-
zation, it reveals that there is low tolerance to guide-target mis-
matches, whereas high efficiency observed in G + C rich genomic 
targets (115).
CRiSPR–Cas9 POTeNTiAL TO TARGeT 
DiSeASeS DeveLOPeD BY ePiGeNeTiC 
ALTeRATiONS
Epigenetics is defined as: molecular mechanisms (heritable) that 
are involved in changing the gene expression without any altera-
tion in DNA sequence (116). This mechanism consists of DNA 
methylation and histone modification that provides conducive 
environment for the stimulation of gene expression, which defines 
their cell proliferation as well as differentiation activity (117). The 
mammalian genome has CpG dinucleotide and DNA methylation 
usually occur at 5′ carbon of the cytosine ring within this dinu-
cleotide (118). Three main DNA methyltransferases (DNMTs) are 
found in mammalian cells: DNMT1, DNMT3A, and DNMT3B. 
DNMT1 is involved in maintaining the pre-existing methylation 
patterns of DNA replication during cell divisions (119); however, 
DNMT3A and DNMT3B involved in the methylation of previ-
ously unmethylated CpGs yielding (120, 121). Another main type 
of epigenetic mechanism is histone modifications, which occur 
on histone protein-specific amino acid (122). To date, discovered 
histone modifications are acetylation, methylation, phospho-
rylation, ADP ribosylation, ubiquitylation, and SUMOylation. 
However, out of these, acetylation and methylation are the best 
known histone modification (123).
It has been established that epigenetic abnormalities are 
involved in the genesis as well as cancer cell progression. Among 
these abnormalities, common one is alteration in the methyla-
tion pattern of genomic DNA. Loss of DNA methylation globally 
10
Shabbir et al. Survival and Evolution of CRISPR–Cas System
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 375
along with hypermethylation at particular loci characterizes a 
major portion of human cancer. Overall, DNA hypomethylation 
could lead to the activation of genes that are silenced in normal 
cells and affect the stability of genome such as viral and parasitic 
transposons. However, DNA hypermethylation, which is gene-
specific, is commonly found in the promoter regions and that 
results in abnormal silencing of PTEN, TP53, BRCA1, ATM, etc. 
(tumor suppressor genes) (124).
In the light of several studies, it was revealed that abnormalities 
in DNA methylation play an important role in the development 
of autoimmune diseases, such as systemic lupus erythematosus 
(SLE). It was reported that in active lupus and lupus like diseases, 
there is abnormal hypomethylation of whole T cell genomic DNA 
(125). When regulatory elements are hypomethylated then they 
may also be involved in abnormal perforin expression. Perforin 
is a cytotoxic molecule of CD4+ T cells from patients having 
active lupus. Perforin may contribute in spontaneous killing of 
macrophages or monocytes that characterizes lupus T cells (126).
These days, numerous non-coding RNA species such as micro 
RNA (miRNA), short interfering RNA (siRNA) are found. These 
RNA species involved in the activation or inhibition of genes that 
play role in the epigenetic regulation of various biological pro-
cesses, such as growth and development (127). In various disease 
conditions, miRNAs are implicated and can be used as to target 
particular gene expression (up or down regulation) according to 
the requirement (128). Currently, successful editing of genetic 
switches is achieved by using CRISPR–cas9 system (129), and 
numerous miRNAs that play role in the progression and devel-
opment of cancer can be targeted specifically with CRISPR–cas9 
system (130). For example, DNTM1 and various other factors 
involved in epigenetic-silencing are excellent contestants to test 
such strategies. As compared with normal cells, cancerous cells 
are more prone to DNTM1 activity, so targeting this enzyme 
should result in limited side effects (131).
To treat cancerous and other deadly genetic diseases, CRISPR–
cas9 system gives a strong hope due to its fabulous outcomes in 
genome-editing technology. The gene expression was suppressed 
when dCas9 (double mutant) bind with a repressor Krupple-
associated box (KRAB); however, its specificity at genomic and 
heterochromatin level was not known until its binding reports 
with HS2 enhancer, having unique role in the expression of 
many globin genes. By observing the highly specific H3K9 tri-
methylation and limited chromatin accessibility of enhancer and 
promoter indicate that for the control of epigenome changes, each 
and every enhancer can be modified successfully (132).
FUTURe DiMeNSiONS
CRISPR–cas system has many useful applications regarding 
immunity and also its biological importance is not less exciting. 
For example, CRISPR–cas system can be acquired by phages 
in order to target the host defense systems; which are an evo-
lutionary and puzzling turn of events (56). There are also some 
phages having genes that play role in the inhibition of CRISPR 
immunity (133). In F. novicida, cas9 can repress an endogenous 
lipoprotein gene in order to promote pathogenesis by preventing 
pro-inflammatory response of the host against this lipoprotein 
(45). CRISPR–cas systems also acts as a barriers against HGT (48, 
57, 134), a fact that highlights significance of CRISPR immunity 
in the evolution of prokaryotes. Hence, one may wonder: now 
what is the next field for CRISPR (135)?
There is no doubt about role of cas9 in genome-editing 
technologies into medical applications, most importantly gene 
therapy which has the potential to make a significant impact 
on human health. Undoubtedly, the translation of cas9-based 
genome-editing technologies into medical applications, most 
notably gene therapy, has the potential to make a significant 
impact on human health (if off-target effects are somehow 
reduced to acceptable levels). The recent advancement in 
understanding the biochemical nature of cas9 targeting (136), 
along with structural insights into cas9:sgRNA complex forma-
tion (137, 138), help us in improving the molecular biological 
tools. In addition, if we look cursory on CRISPR-related pub-
lication and citation rate, it will show us that there is a globally 
awareness about the potential of CRISPR–cas systems, which 
indicate that this system will be used in many molecular 
biology laboratories, if not most. So, due to the acceleration 
of industrial exploitation, commercialization and financial 
investment(s) are setting the platform for a sustainable CRISPR 
revolution.
The cas9 system can be used in animal models for the correc-
tion of their genetic mutation, which, in turn, shows the signifi-
cance of this system in the study of human diseases (113, 139). 
Studies relating to genetics help in identifying the several disease 
and trait-associating genetic variants, and it was found out that 
93% variants are from outside the protein coding sequence. This 
suggests that aberrant regulation of gene expression along with 
non-coding RNAs is the key for causing diseases (140). Hence, 
techniques used for manipulating the gene expression could be 
important for disease research. For in  vivo regulation of gene, 
CRISPR–cas9 system use as an alternative of RNAi for the study of 
gene function, modeling, and therapeutics. Noteworthy, CRISPR 
system have significant benefits when we deal with in vivo activa-
tion studies, such as multiple genes can be activated simply by 
expressing the several small sgRNAs.
For the delivery of CRISPR–cas9 system, currently DNA- and 
RNA-based injection technologies are used, like injection of such 
plasmids are available who has the ability of expressing cas9 
and sgRNA. It is very essential to develop improved or alterna-
tive methods for the delivery of CRISPR–cas9 system into cell 
culture and organisms; so that this system can be used further for 
therapeutic purposes. For example, nanoparticles can be used for 
the delivery of viral vectors or nucleic acid which were previously 
used successfully for the treatment of genetic diseases of liver by 
using other genome-editing systems (141). Cas9 delivery on a 
plasmid or viral vector to a particular tissue in whole organisms 
is also a challenge and it must be resolved, if want to use cas9 for 
clinical purposes (47, 142–145).
In characterized model systems, if CRISPR–cas system is the 
representative of adaptive immunity then its overall impact on 
the host–virus population, genome trajectories, co-evolutionary 
dynamics and their role in evolution, and ecology of microbial 
population in nature is and will continue to be exciting. We also 
anticipate that there is further need to characterize CRISPR 
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model systems, mechanism of action, their genetic elements, and 
functional modules.
CONCLUSiON
In conclusion, bacteria and archaea have evolved their adaptive 
immune system in order to regulate the exchange of invaders 
DNA. In adaptive immune system, CRISPR–cas systems have 
played an important role against foreign genetic elements. 
These systems also play key role in the survival and evolution of 
bacteria. Although, CRISPR–cas systems are diverse from each 
other in term of both phylogenetically and functionally, but still 
in order to cleave invaders DNA, these system relies on three 
common steps: new sequence or spacer integration, biogenesis 
of crRNA, and interference which is crRNA-guided. In addition 
to provide adaptive protection against invaders, self-targeting 
of CRISPR–cas systems can regulate the islands expulsion and 
genomic deletions that might play role in bacterial fitness. Also, 
self-targeting might play role in genome mosaicism, which 
ensures sufficient diversity within bacterial populations for 
rapid niche adaptation. Moreover, by using CRISPR-associated 
surveillance complexes, we can target any sequence of choice. 
Hence, these complexes open a new gateway or provide new 
opportunities about their use in various biotechnological and 
biomedical fields.
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